| 000 | 00000nam 2200000za 4500 |
| 001 | 9.847672 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153507 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171123s2018 onc o f000 0 eng d |
|---|
| 020 | |a9780660239897|z9780660239903 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-179/2017E-PDF |
|---|
| 245 | 00|aHEK293 expression platform (L-10894/11266/11565) |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
|---|
| 300 | |a[1] p. |
|---|
| 500 | |aIssued also in French under title: Plateforme d’expression HEK293 (L-10894/11266/11565). |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"December 2017." |
|---|
| 520 | |a“There is an increasing demand for biopharmaceuticals such as vaccines, humanized monoclonal antibodies, and gene therapy products produced from animal cell culture processes. The NRC’s HEK293 expression system enables the high yield production of viral vector and post-translationally modified recombinant proteins through suspension-growing, serum-free adapted cell lines. It provides an optimized, chemically defined formulation for serum-free suspension culture of this cell line. The cell line can be used in combination with the cumate and coumermycin switches, which enable producers to turn on the expression of a given protein only when needed”--Highlights. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aRecombinant proteins |
|---|
| 693 | 4|aCultures and culture media |
|---|
| 693 | 4|aHEK293 Cells |
|---|
| 710 | 2 |aNational Research Council Canada. |
|---|
| 775 | 08|tPlateforme d’expression HEK293 (L-10894/11266/11565) |w(CaOODSP)9.847676 |
|---|
| 776 | 0#|tHEK293 expression platform |w(CaOODSP)9.847673 |
|---|
| 856 | 40|qPDF|s119 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-179-2017-eng.pdf |
|---|